All companies › MAZE

MAZE · Maze Therapeutics, Inc.

Everything on this page is public record — SEC Form 4 filings and congressional disclosures — alongside any INSIDER SCANNER research case for this company.

Open-market buys0
Open-market sells4
Research cases0
Last filing2026-10-01

Insider flow: Selling only — a count of disclosed transactions, not a rating or a recommendation.

Insider transaction timeline

Every reported transaction, positioned by trade date. Purchases sit above the axis, sales below; circle area is proportional to dollar value. No share-price line is drawn — this feed carries transaction prices only, and a price history inferred from them would imply market data the filings do not contain.

Open-market purchase Open-market sale
2026-09-29 — Dandekar Atul · sold 7,500 @ $27.06 2026-10-01 — Coloma Jason V · sold 2,593 @ $27.02 2026-10-01 — Coloma Jason V · sold 31,908 @ $27.02 2026-10-01 — Bernstein Harold · sold 16,141 @ $26.93
2026-09-292026-10-01

Insider participation

One row per insider, one cell per reported transaction, shaded by value. Repeat buying and activity clustered in time are visible at a glance.

Coloma Jason V Chief Executive Officer, Director
Dandekar Atul CSBO
Bernstein Harold President, R&D & CMO
Included with a free account

The analysis built on top of these filings

The filings above are public record and stay public here. What an account adds for $MAZE is the reading of them — and for this company, that is what the list below says it is, no more.

  • Transaction timelineThe [{'transaction_date': '2026-10-01', 'insider_name': 'Coloma Jason V', 'insider_title': 'Chief Executive Officer, Director', 'transaction_type': 'Open-market sell', 'shares': 2593.0, 'price': 27.0241, 'value': 70073.49, 'is_buy': False}, {'transaction_date': '2026-10-01', 'insider_name': 'Coloma Jason V', 'insider_title': 'Chief Executive Officer, Director', 'transaction_type': 'Open-market sell', 'shares': 31908.0, 'price': 27.021, 'value': 862186.07, 'is_buy': False}, {'transaction_date': '2026-10-01', 'insider_name': 'Bernstein Harold', 'insider_title': 'President, R&D & CMO', 'transaction_type': 'Open-market sell', 'shares': 16141.0, 'price': 26.9341, 'value': 434743.31, 'is_buy': False}, {'transaction_date': '2026-09-29', 'insider_name': 'Dandekar Atul', 'insider_title': 'CSBO', 'transaction_type': 'Open-market sell', 'shares': 7500.0, 'price': 27.0561, 'value': 202920.75, 'is_buy': False}] reported transactions plotted over the window rather than listed, so concentration is visible.

Not available for MAZE today: no reported open-market purchases in this window, so there is no insider cost basis to compute; no research case — nothing here has cleared the scoring threshold. Both appear on this page on their own if that changes.

A free account opens all of it.

Not financial advice. This page reports public filings and past research output. It is not a recommendation to buy or sell, and no price target here is a prediction. Trade at your own risk.